Michael V. Seiden, MD, PhD

Michael V. Seiden, MD, PhD was appointed to the Board in July 2023 and serves as a member of the Audit and Risk Management, Remuneration, and Nomination Committees. Dr. Seiden is a Board Certified Medical Oncologist with a broad collection of leadership positions across the cancer care and business ecosystem, ranging from the science that underpins oncology drug development through the economics of cancer care delivery.

Currently, he serves as the CEO and Board Director of Gladius Therapeutics a clinical stage oncology drug development company. Previous roles included serving as the president of The US Oncology Network, a McKesson owned company that includes the largest collection of community based oncology care practices in the US. Prior to his role as President of US Oncology, Dr. Seiden served as the senior vice president and Chief Medical Officer of The US Oncology Network. Before joining The Network, he served as CEO and President of Fox Chase Cancer Center, a National Cancer Institute-designated Comprehensive Cancer Center research facility and hospital in Philadelphia as well as a founding member of the NCCN. Prior to Fox Chase, Dr. Seiden spent many years practicing oncology and conducting research at Massachusetts General Hospital and Harvard Medical School, where he served as Chief of the Clinical Research Unit and Associate Professor in Medicine at Harvard University.

Dr. Seiden received his undergraduate degree in Chemistry from Oberlin College and a master, medical and Ph.D. degrees from Washington University. He completed his residency at Massachusetts General Hospital, fellowships in medical oncology and bone marrow transplant at Dana Farber Cancer Institute, with post-doctoral fellowship training at Brigham and Women’s Hospital in the department of pathology.